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Introduction
Cryopyrin-associated periodic syndromes (CAPS) are
characterized by apparently unprovoked attacks of fever,
rashes, and musculoskeletal and sensorineural inflamma-
tion accompanied by high acute-phase reactants. Excessive
interleukin-1 (IL-1) signaling appears to be a constant fea-
ture in the pathomechanism of the disease, driven by a
gain-of-function mutation in the NLRP3 gene. Familial
Mediterranean fever (FMF) is a auto-inflammatory disor-
der characterised by recurring, self-limited episodes of
fever and serositis resulting in abdominal, chest, joint and
muscular pain due to mutation of MEFV. Colchicine is
generally safe, nevertheless, 5-10% patients do not respond
to treatment. IL-1blockade is the treatment of choice of
CAPS and colchicine resistant FMF. IL-1 receptor antago-
nist-anakinra, human dimeric protein that incorporates
the extra-cellular domain of IL-1 receptor and IL-receptor
accessory protein-rilonacept, and a human anti-IL-1b
monoclonal antibody-canakinumab are biologic agents
used for this aim.
We report the effect of anti-interleukin 1 treatment
(canakinumab, anakinra) in 12 patients (2 CAPS cases
and 10 FMF cases of resistant to colchicine therapy).
Patients and methods
We evaluated 12 anti-IL1 used patients diagnosed CAPS
and FMF. Their demographic findings, the course of the
disease, genetic analysis, therapy, were recorded from their
hospital records.
Results
Two patients (1 male, 1 female) were diagnosed with Sys-
temic Onset Poliarticular Juvenile Idiopathic Arthritis
when they were 2 years old. They were treated with this
diagnose up to two years. After the reevaluation of patients
according to the new literature, they diagnosed CAPS and
canakinumab were used for therapy. Both of them has
been followed for 1.5 year with clinical and laboratory
remission. Ten FMF patients were evaluated for therapy in
this study, and we observed that 9 of them have a homozy-
gous M694V mutation and one of them has got M694V/
M680I coumpound heterozygous mutation. Their age,
symptoms onset age, and age at the diagnosis were 12.8±5,
3.2±1.9, 6.7±3.4 years respectively. The duration of colchi-
cine was 5.9±3.5 year. We used canacinumab (5 patients)
and anakinra (5 patients) because their disease was resis-
tant to colchicine therapy. The median duration of IL1
inhibitors was 7 months. All of them has been followed
with clinical and laboratory remission.
Conclusions
Interleukin-1 inhibitors should be selected for treatment
of CAPS and they may be good candidates when looking
for an alternative or supplementary treatment to colchi-
cine in FMF. These observations highlight the need for
controlled trials to further evaluate the safety and efficacy
of interleukin-1 antagonists in FMF patients.
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